Chairs: A. Kronbichler (Innsbruck, Austria), B. Hohenstein (Villingen-Schwenningen, Germany)
09:00-09:05
P-01
*Z. Tsonchev, M. Bozhilova, M. Daskalov, P. Kenarov, A. Momchilova, A. Alexandrov (Sofia, Bulgaria)
Experience for treatment thrombotic thrombocytopenic purpura disease with plasmapheresis using nanotechnology membrane
09:05-09:10
P-02
*M. Lánská, M. Bláha, I. Krčmova, P. Žák (Hradec Kralove, Czech Republic)
Extracorporeal IgE Immunoadsorption in Alleric Asthma – first centre experience
09:10-09:15
P-03
O. Dmitrieva, O. Afanasieva, P. Levashov, *S. Pokrovsky (Moscow, Russian Federation)
Comparative in vitro analysis of three systems for endotoxin removal (LPS adsorption)
09:15-09:20
P-04
*I. Adamova, M. Afanasieva, E. Utkina, Y. Beresttskaya, N. Pokrovsky, O. Afanasieva, S. Pokrovsky (Moscow, Russian Federation)
Sorbents for selective removal of sFlt-1 to treat preeclampsia
09:20-09:25
P-05
*O. Afanasieva, M. Afanasieva, I. Adamova, E. Vichrova, N. Pokrovsky, P. Levashov, S. Pokrovsky (Moscow, Russian Federation)
Antibodies and synthetic ligands containing sorbents for Ig apheresis (in vitro comparison study)
09:25-09:30
P-06
*M. Scully (London, UK), S. Cataland (Columbus, United States), F. Peyvandi (Milano, Italy), P. Coppo (Paris, France), P. Knöbl (Vienna, Austria), J. Kremer Hovinga (Bern, Switzerland), A. Metjian (Durham, United States), J. de la Rubia (Valencia, Spain), K. Pavenski (Toronto, Canada), F. Callewaert, D. Biswas, H. De Winter, R.K. Zeldin (Ghent, Belgium)
Caplacizumab for acquired thrombotic thrombocytopenic purpura – results of the phase 3 HERCULES study
09:30-09:35
P-07
*C. Schmidt- Rimpler, S. Uthoff, D. Kramer, M. Fischer (Bad Homburg, Germany)
Immunoadsorption in Dilated Cardiomyopathy – what the literature tells us
09:35-09:40
P-08
*S. Bardakov, A. Sokolov, D. Skulyabin, M. Zacharov, S. Lapin, A. Mazing (St. Petersburg, Russian Federation)
Effects of therapeutic apheresis methods in treatment of STIFF-person syndrom
09:40-09:45
P-09
*F. Kälble, L. Pego da Silva, M. Schaier, M. Zeier, A. Mehrabi, C. Süsal, C. Morath (Heidelberg, Germany)
Outcomes following living donor kidney transplantation in patients with donor-specific HLA antibodies after desensitization with immunoadsorption
09:45-09:50
P-10
*C. A. Rae, J. Barnes, J. A. Diaz Aunon, J. Simoni (Rapid City, United States)
A novel smart adsorbent for extracorporeal blood purification therapy
Chairs: B. Jaeger (Mühlheim a.d.Ruhr, Germany) , A. Vogt (Munich, Germany)
10:30-10:35
P-11
*J. Otto, D. Handschel, G. Maniera (Cologne, Germany)
Removal of Xanthomas and Xanthelasmas by LDL-Apheresis in a Case of severe Familial Hypercholesterolemia (FH)
10:35-10:40
P-12
*M. Chocholous, A. Handisurya (Vienna, Austria)
Direct Adsorption of Lipoproteins (DALI®) Apheresis for Elevated Lipoprotein(a) During Pregnancy – A Case Report
10:40-10:45
P-13
*O. Afanasieva, O. Razova, M. Ezhov, A. Popova, E. Utkina, M. Afanasieva, S. Pokrovsky (Moscow, Russian Federation)
Lipoprotein(a), PCSK9 and complex Lp(a)-PCSK9 plasma levels in hypercholesterolemia patients
10:45-10:50
P-14
*N. K. Walleczek, K. Arbeiter, P. R. Espina, T. Hörtenhuber, A. Kreissl, S. Greber-Platzer (Vienna, Austria)
Effects of a newly established lipid apheresis for a young homozygous familial hypercholesterolemia population at the Department of Pediatrics and Adolescent Medicine in Vienna
10:50-10:55
P-15
*A. Giurgea, E. Karkutli, H. Sinzinger (Vienna, Austria)
Left ventricular ejection fraction after 1 year Lipoprotein apheresis
10:55-11:00
P-16
*A. Klink, A. Hilge, S. Volkholz, K. Maier, H. Jütte, S. Rummler (Jena, Germany)
Lipoprotein-Apheresis with the Spectra Optia Apheresis System
11:00-11:05
P-17
V. E. Varga, H. Lőrincz, A. Szentpéteri, L. Juhász, I. Seres, J. Balla, G. Paragh, *M. Harangi (Debrecen, Hungary)
Changes in some pro- and antioxidant parameters after selective LDL apheresis
11:05-11:10
P-18
*T. Berent (Vienna, Austria), M. Halilovic (Vienna, Austria), R. Berent (Bad Ischl, Austria), H. Sinzinger (Vienna, Austria)
Intensified treatment regimen of regular lipoprotein apheresis in patients with elevated lipoprotein(a) and clinically progressive atherosclerotic disease: two case reports
11:10-11:15
P-19
*E. Ovchinnikova, I. Adamova, E. Utkina, P. Levashov, S. Pokrovsky (Moscow, Russian Federation)
Affinity sorbents based on tryptamine and tyramine for practical use in medicine and biotechnology
11:15-11:20
P-20
*D. Dlouha, J. Pitha, Z. Eretova, J. Hubacek, A. Parikova, O. Viklicky (Prague, Czech Republic)
Effect of LDL/Lp(a) apheresis treatment on plasma levels of miRNAs in patients with high Lp(a), a follow-up study
11:20-11:25
P-21
*J. Piel, K. Lilienthal (Tallinn, Estonia)
Lipoprotein Apheresis Administration Experience in Estonia: Case Report
11:25-11:30
P-22
*U. Schatz, S. Fischer, S. Tselmin, G. Müller, U. Julius, S. R. Bornstein (Dresden, Germany)
Risk factor constellation in patients with premature cardiovascular events
Chairs: U. Julius (Dresden, Germany), H. Sinzinger (Vienna, Austria)
P-23
This poster has been withdrawn.
P-24
This poster has been withdrawn.
13:45-13:52
P-25
*Á. Diószegi, M. Nánásy-Vass, N. Németh, M. Káplár, K. Veres, P. Soltész (Debrecen, Hungary)
Rheopheresis in diabetic foot ulceration– Results of 3 years follow-up
13:52-14:00
P-26
*B. Stegmayr and the WAA Registry Study Group (Umea, Sweden et al.)
Data from the WAA register – Up date of patients 21 years and older
14:00-14:08
P-27
*K. Artinger, T. Niedrist, A. Meinitzer, A. R. Rosenkranz, K. Eller (Graz, Austria)
Iron deficiency in patients undergoing immunoadsorption
14:08-14:16
P-28
*M. Blaha, H. Langrova, V. Blaha, M. Lanska, J. Studnicka, A. Stepanov (Hradec Králové, Czech Republic)
Dynamics of proprotein convertase subtilisin kexin 9 (PCSK9) in the treatment with rheopheresis in age related macular degeneration
14:16:14:23
P-29
*D. Dlouha (Prague), I. Prochazkova (Prague), M. Blaha (Hradec Králové), V. Blaha (Hradec Králové), I. Fatorova (Hradec Králové), J. Hubacek (Prague), J. Pitha (Prague)
Amount of RNA contamination in samples from the rinse of the apheresis column
14:23-14:30
P-30
*T. Berent (Vienna, Austria), S. Steiner (Leipzig, Germany), R. Berent (Bad Ischl, Austria), H. Sinzinger (Vienna, Austria)
Anatomical mapping of muscle-related side-effects of statins
14:30-14:37
P-31
*M. Nagel, M. Benke, I. Duma, C. Vlad, T. Lucke, S. Nagorka (Weißwasser, Germany)
Molecular genetic diagnosis helps to predict the outcome of PCSK9 inhibitor therapy
14:37-14:45
P-32
*S. Perrone, R. Brunelli, G. Perrone, P. Galoppi, I. Zannini, S. Di Giacomo, C. Morozzi, C. Stefanutti (Rome, Italy)
A successful term pregnancy with severe hypertriglyceridemia and acute pancreatitis: case report and literature review
Explanation:
*T. Berent = Main author
R. Berent = Presenting author
